

OSI SYSTEMS INC  
Form 10-Q  
October 30, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 10-Q**

(Mark one)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2008**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number 0-23125**

**OSI SYSTEMS, INC.**

**(Exact name of registrant as specified in its charter)**

**California  
(State or other jurisdiction of  
incorporation or organization)**

**33-0238801  
(I.R.S. Employer  
Identification Number)**

**12525 Chadron Avenue  
Hawthorne, California 90250  
(Address of principal executive offices)  
(310) 978-0516**

**(Registrant's telephone number, including area code)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No   
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of October 28, 2008, there were 17,839,522 shares of the registrant's common stock outstanding.



**OSI SYSTEMS, INC.  
INDEX**

	<b>PAGE</b>
<b><u>PART I FINANCIAL INFORMATION</u></b>	
<u>Item 1 Condensed Consolidated Financial Statements</u>	
<u>Condensed Consolidated Balance Sheets at June 30, 2008 and September 30, 2008</u>	3
<u>Condensed Consolidated Statements of Operations for the three months ended September 30, 2007 and 2008</u>	4
<u>Condensed Consolidated Statements of Cash Flows for the three months ended September 30, 2007 and 2008</u>	5
<u>Notes to Condensed Consolidated Financial Statements</u>	6
<u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
<u>Item 3 Quantitative and Qualitative Disclosures about Market Risk</u>	22
<u>Item 4 Controls and Procedures</u>	23
<b><u>PART II OTHER INFORMATION</u></b>	
<u>Item 1 Legal Proceedings</u>	24
<u>Item 1A Risk Factors</u>	24
<u>Item 6 Exhibits</u>	24
<u>Signatures</u>	25
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Condensed Consolidated Financial Statements**

**OSI SYSTEMS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands, except share amounts)  
(Unaudited)

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$ 18,232	\$ 21,048
Accounts receivable, net	156,781	137,116
Other receivables	3,258	3,795
Inventories	144,807	148,599
Deferred income taxes	19,313	19,183
Prepaid expenses and other current assets	14,064	19,052
Total current assets	356,455	348,793
Property and equipment, net	47,191	45,480
Goodwill	60,408	60,624
Intangible assets, net	34,495	32,847
Other assets	9,092	10,504
Total assets	\$ 507,641	\$ 498,248
<b>LIABILITIES AND SHAREHOLDERS EQUITY</b>		
Current Liabilities:		
Bank lines of credit	\$ 18,657	\$ 9,000
Current portion of long-term debt	6,593	7,094
Accounts payable	75,320	71,328
Accrued payroll and employee benefits	20,896	19,505
Advances from customers	6,746	20,818
Accrued warranties	11,597	10,705
Deferred revenue	7,414	7,128
Other accrued expenses and current liabilities	14,274	11,045
Total current liabilities	161,497	156,623
Long-term debt	49,091	46,541
Other long-term liabilities	17,804	19,095
Total liabilities	228,392	222,259
Minority interest	1,228	1,198
Commitment and contingencies (Note 7)		

Shareholders Equity:

Edgar Filing: OSI SYSTEMS INC - Form 10-Q

Preferred stock, no par value-authorized, 10,000,000 shares; no shares issued or outstanding		
Common stock, no par value-authorized, 100,000,000 shares; 17,740,057 and 17,837,846 shares, issued and outstanding, at June 30, 2008 and September 30, 2008, respectively	224,581	227,373
Retained earnings	41,972	42,104
Accumulated other comprehensive income	11,468	5,314
Total shareholders' equity	278,021	274,791
Total liabilities and shareholders' equity	\$ 507,641	\$ 498,248

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**OSI SYSTEMS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(in thousands, except per share amount data)  
(Unaudited)

	<b>For the Three Months Ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Revenues	\$ 131,013	\$ 148,161
Cost of goods sold	86,903	98,526
Gross profit	44,110	49,635
Operating expenses:		
Selling, general and administrative expenses	36,211	37,571
Research and development	9,729	10,213
Impairment, restructuring, and other charges	85	801
Total operating expenses	46,025	48,585
Income (loss) from operations	(1,915)	1,050
Interest expense, net	(1,089)	(895)
Income (loss) before benefit for income taxes and minority interest	(3,004)	155
Provision (benefit) for income taxes	(1,055)	53
Minority interest in net earnings (losses) of consolidated subsidiaries	118	(30)
Net income (loss)	\$ (2,067)	\$ 132
Income (loss) per share:		
Basic	\$ (0.12)	\$ 0.01
Diluted	\$ (0.12)	\$ 0.01
Shares used in per share calculation:		
Basic	17,171	17,797
Diluted	17,171	18,166

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**OSI SYSTEMS, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(amounts in thousands)  
(Unaudited)

	<b>For the Three Months Ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Cash flows from operating activities:		
Net income (loss)	\$ (2,067)	\$ 132
Adjustments to reconcile net income (loss) to net cash provided (used) by operating activities:		
Depreciation and amortization	4,547	4,359
Stock based compensation expense	1,095	1,193
Provision for losses on accounts receivable	145	1,144
Minority interest in net earnings (losses) of consolidated subsidiaries	118	(30)
Equity in (earnings) loss of unconsolidated affiliate	(81)	25
Deferred income taxes	(3,490)	(294)
Other	(24)	12
Changes in operating assets and liabilities:		
Accounts receivable	4,510	14,288
Other receivables	876	(1,497)
Inventories	(14,031)	(9,228)
Prepaid expenses and other current assets	(4,268)	(5,528)
Accounts payable	8,974	(1,643)
Accrued payroll and employee benefits	(369)	(1,054)
Advances from customers	1,661	14,825
Accrued warranties	498	(492)
Deferred revenue	(789)	1,337
Other accrued expenses and current liabilities	(949)	(2,863)
Net cash provided (used) by operating activities	(3,644)	14,686
Cash flows from investing activities:		
Acquisition of property and equipment	(2,600)	(2,186)
Proceeds from the sale of property and equipment	88	30
Buyback of subsidiary stock	(443)	
Acquisition of intangible and other assets	(853)	(727)
Net cash used in investing activities	(3,808)	(2,883)
Cash flows from financing activities:		
Net payments on bank lines of credit	(16,775)	(9,413)
Proceeds from long-term debt	44,883	
Payments on long-term debt	(22,488)	(1,794)
Payments on capital lease obligations	(341)	(263)
Proceeds from exercise of stock options and employee stock purchase plan	884	1,599

Edgar Filing: OSI SYSTEMS INC - Form 10-Q

Net cash provided (used) by financing activities	6,163	(9,871)
Effect of exchange rate changes on cash	(47)	884
Net increase (decrease) in cash and cash equivalents	(1,336)	2,816
Cash and cash equivalents-beginning of period	15,980	18,232
Cash and cash equivalents-end of period	\$ 14,644	\$ 21,048
Supplemental disclosure of cash flow information:		
Cash paid during the year for:		
Interest	\$ 1,133	\$ 1,063
Income taxes	\$ 1,027	\$ 1,139

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**OSI SYSTEMS, INC. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Basis of Presentation**

*Description of Business*

OSI Systems, Inc., together with its subsidiaries (the Company), is a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications. The Company sells its products in diversified markets, including homeland security, healthcare, defense and aerospace.

The Company has three operating divisions: (i) Security, providing security inspection systems; (ii) Healthcare, providing patient monitoring, diagnostic cardiology and anesthesia systems; and (iii) Optoelectronics and Manufacturing, providing specialized electronic components for the Security and Healthcare divisions as well as for applications in the defense and aerospace markets, among others.

Through its Security division, the Company designs, manufactures and markets security and inspection systems worldwide to end users primarily under the Rapiscan Systems trade name. Rapiscan Systems products are used to inspect baggage, cargo, vehicles and other objects for weapons, explosives, drugs and other contraband and to screen people. These products are also used for the safe, accurate and efficient verification of cargo manifests for the purpose of assessing duties and monitoring the export and import of controlled materials. Rapiscan Systems products fall into four categories: baggage and parcel inspection, cargo and vehicle inspection, hold (checked) baggage screening and people screening.

Through its Healthcare division, the Company designs, manufactures and markets patient monitoring, diagnostic cardiology and anesthesia systems worldwide to end users, primarily under the Spacelabs trade name. These products are used by care providers in critical care, emergency and perioperative areas within hospitals as well as physicians offices, medical clinics and ambulatory surgery centers. The Company's Healthcare division also offers centralized cardiac safety core laboratory services in connection with clinical trials by or on behalf of pharmaceutical companies and clinical research organizations.

Through its Optoelectronics and Manufacturing division, the Company designs, manufactures and markets optoelectronic devices and value-added manufacturing services worldwide for use in a broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging and diagnostics, computed tomography (CT), fiber optics, telecommunications, gaming, office automation, computer peripherals and industrial automation. The Company sells optoelectronic devices primarily under the OSI Optoelectronics trade name and performs value-added manufacturing services primarily under the OSI Electronics trade name. This division provides products and services to original equipment manufacturers as well as to the Company's own Security and Healthcare divisions. The Optoelectronics and Manufacturing division also designs toll and traffic management systems under the OSI LaserScan trade name and systems for measuring bone density under the Osteometer trade name.

*Basis of Presentation*

The condensed consolidated financial statements include the accounts of OSI Systems, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared by the Company, without audit, pursuant to Accounting Principles Board Opinion No. 28, Interim Financial Reporting and the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of the Company's management, all adjustments, consisting of only normal and recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the periods presented have been included. These condensed consolidated financial statements and the accompanying notes should be read in conjunction with the audited condensed consolidated financial statements and accompanying notes included in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2008, filed with the Securities and Exchange Commission on August 28, 2008. The results of operations for the three months ended September 30, 2008 are not necessarily indicative of the operating

results to be expected for the full fiscal year or any future periods.

6

---

**Table of Contents***Per Share Computations*

The Company computes basic earnings per share by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. The Company computes diluted earnings per share by dividing net income available to common shareholders by the sum of the weighted average number of common and dilutive potential common shares outstanding. Potential common shares consist of restricted shares and shares issuable upon the exercise of stock options or warrants under the treasury stock method. Stock options and warrants to purchase a total of 2.7 million and 1.1 million shares of common stock for the three months ended September 30, 2007 and 2008, respectively, were not included in diluted earnings per share calculations because to do so would have been antidilutive. The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	<b>Three months Ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Net income (loss)	\$ (2,067)	\$ 132
Effect of dilutive interest in subsidiary stock	(1)	
Net income (loss) available to common shareholders	\$ (2,068)	\$ 132
Weighted average shares outstanding basic	17,171	17,797
Dilutive effect of stock options and warrants		369
Weighted average shares outstanding diluted	17,171	18,166
Basic earnings (loss) per share	\$ (0.12)	\$ 0.01
Diluted earnings (loss) per share	\$ (0.12)	\$ 0.01

*Comprehensive Income*

Comprehensive loss is computed as follows (in thousands):

	<b>Three months Ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Net income (loss)	\$ (2,067)	\$ 132
Gain on foreign currency forward contract		55
Foreign currency translation adjustments	1,645	(6,408)
Minimum pension liability adjustment	(174)	199
Comprehensive loss	\$ (596)	\$ (6,022)

As of September 30, 2008, the Company had an \$8.3 million foreign currency forward contract to sell Polish zloty in anticipation of the sale and settlement in the second quarter of fiscal 2009 of products denominated in Polish zloty. Pursuant to SFAS No. 133 Accounting for Derivative Instruments and Hedging Activities (as amended) (SFAS 133), the entire amount of this forward contract is considered a cash flow hedge. As a result, the gain on this foreign currency forward contract for the three months ended September 30, 2008 of \$0.1 million has been reported as a component of other comprehensive income in the condensed consolidated financial statements.

*Recent Accounting Pronouncements*

In September 2006, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 157, Fair Value Measurements (SFAS 157), which clarifies the definition of fair value whenever another standard requires or permits assets or liabilities to be measured at fair value. Specifically, the standard clarifies that fair value should be based on the assumptions market participants would use when pricing the asset or liability, and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. SFAS 157 does not expand the use of fair value to any new circumstances, and must be applied on a prospective basis except in certain cases. The standard also requires expanded financial statement disclosures about fair value measurements, including disclosure of the methods used and the effect on earnings.

**Table of Contents**

In February 2008, FASB Staff Position (FSP) FAS No. 157-2, Effective Date of FASB Statement No. 157 (FSP 157-2) was issued. FSP 157-2 defers the effective date of SFAS 157 to fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, for all nonfinancial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Examples of items within the scope of FSP 157-2 are nonfinancial assets and nonfinancial liabilities initially measured at fair value in a business combination (but not measured at fair value in subsequent periods), and long-lived assets, such as property, plant and equipment and intangible assets measured at fair value for an impairment assessment under SFAS 144.

The partial adoption of SFAS 157 on July 1, 2008 with respect to financial assets and financial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis did not have a material impact on the Company's condensed consolidated financial statements. The Company is in the process of analyzing the potential impact of SFAS No. 157 relating to its planned July 1, 2009 adoption of the remainder of the standard.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements, an amendment of ARB No. 51 (SFAS 160). The new standard changes the accounting and reporting of noncontrolling interests, which have historically been referred to as minority interests. SFAS 160 requires that noncontrolling interests be presented in the consolidated balance sheets within shareholders' equity, but separate from the parent's equity, and that the amount of consolidated net income attributable to the parent and to the noncontrolling interest be clearly identified and presented in the consolidated statements of income. Any losses in excess of the noncontrolling interest's equity interest will continue to be allocated to the noncontrolling interest. Purchases or sales of equity interests that do not result in a change of control will be accounted for as equity transactions. Upon a loss of control, the interest sold, as well as any interest retained, will be measured at fair value, with any gain or loss recognized in earnings. In partial acquisitions, when control is obtained, the acquiring company will recognize at fair value, 100% of the assets and liabilities, including goodwill, as if the entire target company had been acquired. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008, with early adoption prohibited. The new standard will be applied prospectively, except for the presentation and disclosure requirements, which will be applied retrospectively for all periods presented. The Company has not yet determined the impact, if any, that this statement will have on its condensed consolidated financial statements and will adopt the standard at the beginning of fiscal 2010.

In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133 (SFAS 161). The standard expands the disclosure requirements of SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, and requires qualitative disclosures about the objectives and strategies for using derivatives, quantitative disclosures about the fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. The Company is in the process of analyzing this new standard, which will be effective for the Company in the third quarter of fiscal 2009.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations (SFAS 141(R)). The new standard changes the accounting for business combinations in a number of significant respects. The key changes include the expansion of transactions that will qualify as business combinations, the capitalization of in-process research and development (IPR&D) as an indefinite-lived asset, the recognition of certain acquired contingent assets and liabilities at fair value, the expensing of acquisition costs, the expensing of costs associated with restructuring the acquired company, the recognition of contingent consideration at fair value on the acquisition date, and the recognition of post-acquisition date changes in deferred tax asset valuation allowances and acquired income tax uncertainties as income tax expense or benefit. SFAS 141(R) is effective for business combinations that close in years beginning on or after December 15, 2008, with early adoption prohibited. The Company has not yet determined the impact, if any, that this statement will have on its condensed consolidated financial statements and will adopt the standard at the beginning of fiscal 2010.

In May 2008, the FASB issued SFAS No. 162, Hierarchy of Generally Accepted Accounting Principles (SFAS 162). This statement is intended to improve financial reporting by identifying a consistent framework, or hierarchy, for

selecting accounting principles to be used in preparing financial statements of nongovernmental entities that are presented in conformity with GAAP. This statement will be effective 60 days following the Securities and Exchange Commission's approval of the Public Company Accounting Oversight Board amendment to AU Section 411, "The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles." The Company believes that SFAS 162 will have no effect on its condensed consolidated financial statements.

**Table of Contents****2. Balance Sheet Details**

The following tables provide details of selected balance sheet accounts (in thousands):

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
<b>Accounts receivable</b>		
Trade receivables	\$ 158,326	\$ 139,372
Receivables related to long term contracts unbilled costs and accrued profit on progress completed	758	880
<b>Total</b>	159,084	140,252
Less: allowance for doubtful accounts	(2,303)	(3,136)
<b>Accounts receivable, net</b>	<b>\$ 156,781</b>	<b>\$ 137,116</b>

The Company expects to bill and collect the receivables for unbilled costs and accrued profits at September 30, 2008, during the next twelve months.

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
<b>Inventories, net</b>		
Raw materials	\$ 70,339	\$ 71,059
Work-in-process	35,326	34,729
Finished goods	39,142	42,811
<b>Total</b>	<b>\$ 144,807</b>	<b>\$ 148,599</b>

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
<b>Property and equipment, net</b>		
Land	\$ 6,246	\$ 5,877
Buildings	8,233	7,921
Leasehold improvements	10,068	10,158
Equipment and tooling	51,280	50,980
Furniture and fixtures	5,243	5,115
Computer equipment	15,856	16,807
ERP software	11,500	11,260
<b>Total</b>	108,426	108,118
Less: accumulated depreciation and amortization	(61,235)	(62,638)
<b>Property and equipment, net</b>	<b>\$ 47,191</b>	<b>\$ 45,480</b>

**3. Goodwill and Intangible Assets**

Edgar Filing: OSI SYSTEMS INC - Form 10-Q

The changes in the carrying value of goodwill for the three month period ended September 30, 2008, are as follows (in thousands):

	<b>Security</b>	<b>Healthcare</b>	<b>Optoelectronics and Manufacturing</b>	<b>Consolidated</b>
Balance as of June 30, 2008	\$ 17,692	\$ 35,569	\$ 7,147	\$ 60,408
Goodwill acquired or adjusted during the period		949		949
Foreign currency translation adjustment	(378)	(352)	(3)	(733)
Balance as of September 30, 2008	\$ 17,314	\$ 36,166	\$ 7,144	\$ 60,624

**Table of Contents**

In fiscal 2008, the Company repurchased all minority interests in its Spacelabs Healthcare subsidiary. In conjunction with these repurchases, a preliminary allocation of the purchase price in excess of the book value of the minority interest was recorded as of June 30, 2008. During the three months ended September 30, 2008, the Company completed its evaluation, resulting in the following purchase price allocation (in thousands):

	<b>Preliminary Allocation</b>	<b>Adjustments</b>	<b>Final Allocation</b>
Goodwill	\$ 9,155	929	\$ 10,084
Developed technology	2,219	355	2,574
Customer relationships	1,442	11	1,453
Trademarks	3,994	(1,697)	2,297
Deferred taxes	(2,679)	402	(2,277)
Total excess purchase price	\$ 14,131		\$ 14,131

Intangible assets consisted of the following (in thousands):

	<b>Weighted Average Lives</b>	<b>June 30, 2008</b>			<b>September 30, 2008</b>		
		<b>Gross Carrying Value</b>	<b>Accumulated Amortization</b>	<b>Intangibles Net</b>	<b>Gross Carrying Value</b>	<b>Accumulated Amortization</b>	<b>Intangibles Net</b>
Amortizable assets:							
Software development costs	5 years	\$ 6,265	\$ 2,634	\$ 3,631	\$ 7,181	\$ 2,775	\$ 4,406
Patents	8 years	451	298	153	573	306	267
Core technology	10 years	2,684	911	1,773	2,477	903	1,574
Developed technology	13 years	17,276	5,430	11,846	17,509	5,851	11,658
Customer relationships/ backlog	7 years	9,582	3,697	5,885	9,532	4,001	5,531
Total amortizable assets		36,258	12,970	23,288	37,272	13,836	23,436
Non-amortizable assets:							
Trademarks		11,207		11,207	9,411		9,411
Total intangible assets		\$ 47,465	\$ 12,970	\$ 34,495	\$ 46,683	\$ 13,836	\$ 32,847

Amortization expense related to intangibles assets was \$0.9 million and \$1.0 million for the three months ended September 30, 2007 and 2008, respectively. At September 30, 2008, the estimated future amortization expense was as follows (in thousands):

2009 (remaining 9 months)	\$ 2,905
2010	3,818
2011	3,792
2012	3,693

2013	2,896
2014	2,011
2015 and thereafter	4,321
Total	\$ 23,436

#### 4. Borrowings

The Company maintains a credit agreement with certain lenders allowing for borrowings of up to \$124.5 million. The credit agreement consists of a \$74.5 million, five-year, revolving credit facility (including a \$45 million sub-limit for letters-of-credit) and a \$50 million five-year term loan. Borrowings under the agreement bear interest at either (i) the London Interbank Offered Rate (LIBOR) plus between 2.00% and 2.50% or (ii) the bank's prime rate plus between 1.00% and 1.50%. The rates are determined based on the Company's consolidated leverage ratio. As of September 30, 2008, the effective, weighted-average interest rate under the credit agreement was 5.5%. The Company's borrowings under the credit agreement are guaranteed by substantially all of the Company's direct and indirect wholly-owned subsidiaries and are secured by substantially all of the Company's and its subsidiary guarantors' assets. The agreement contains various representations, warranties, affirmative, negative and financial covenants, and conditions of default customary for financing agreements of this type. As of September 30, 2008, \$46.5 million was outstanding under the term loan, \$9.0 million was outstanding under the revolving credit facility, and \$13.8 million was outstanding under the letter-of-credit facility.

**Table of Contents**

Several of the Company's foreign subsidiaries maintain bank lines-of-credit, denominated in local currencies, to meet short-term working capital requirements and for the issuance of letters-of-credit. As of September 30, 2008, \$22.9 million was outstanding under these letter-of-credit facilities, while no debt was outstanding. As of September 30, 2008, the total amount available under these credit facilities was \$32.6 million, with a total cash borrowing sub-limit of \$8.1 million. As of September 30, 2008, the weighted average interest rate of these facilities was 7.1% per annum,

In December 2004, the Company entered into a bank loan of \$5.3 million to fund the acquisition of land and buildings in the U.K. The loan is payable over a 20-year period, with quarterly installments of £34,500 (approximately \$63,000 as of September 30, 2008). The loan bears interest at British pound-based LIBOR plus 1.2%, payable on a quarterly basis. As of September 30, 2008, \$4.1 million remained outstanding under this loan at an interest rate of 7.5% per annum.

Long-term debt consisted of the following (in thousands):

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
Five-year term loan due in fiscal 2013	\$ 47,763	\$ 46,513
Twenty-year term loan due in fiscal 2025	4,539	4,126
Capital leases	2,193	1,938
Other	1,189	1,058
	55,684	53,635
Less current portion of long-term debt	6,593	7,094
	\$ 49,091	\$ 46,541

**5. Stock-based Compensation**

As of September 30, 2008, the Company maintained the 2006 Equity Participation Plan of OSI Systems. In addition, the Company maintains and administers an employee stock purchase plan.

The Company recorded stock-based-compensation expense in accordance with SFAS No. 123(R) Share-Based Payment in the condensed consolidated statement of operations as follows (in thousands):

	<b>Three Months Ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Cost of goods sold	\$ 52	\$ 60
Selling, general and administrative	984	1,065
Research and development	59	68
	\$ 1,095	\$ 1,193

As of September 30, 2008, total unrecognized compensation cost related to non-vested, share-based compensation arrangements granted was approximately \$6.7 million. The Company expects to recognize these costs over a weighted-average period of 2.4 years.

**Table of Contents****6. Retirement Benefit Plans**

The Company sponsors a number of qualified and nonqualified defined benefit pension plans for its employees. The benefits under these plans are based on years of service and an employee's highest twelve months' compensation during the last five years of employment. The components of net periodic pension expense are as follows (in thousands):

	<b>Three Months Ended</b>	
	<b>September 30,</b>	
	<b>2007</b>	<b>2008</b>
Service cost	\$ 71	\$ 316
Interest cost	120	79
Expected return on plan assets	(92)	(28)
Amortization of net loss	38	26
Net periodic pension expense	\$ 137	\$ 393

For the three months ended September 30, 2007 and 2008, the Company made contributions of \$0.1 million and \$0.4 million, respectively, to these defined benefit plans.

In addition, the Company sponsors several defined contribution pension plans. For the three months ended September 30, 2007 and 2008, the Company made contributions of \$0.6 million and \$0.7 million, respectively, to these defined contribution plans.

**7. Commitments and Contingencies***Legal Proceedings*

In November 2002, L-3 Communications Corporation brought suit against the Company in the District Court for the Southern District of New York seeking a declaratory judgment that L-3 Communications Corporation had not breached its obligations to us concerning the acquisition of PerkinElmer's Security Detection Systems Business. The Company asserted counterclaims against L-3 Communications Corporation for, among other things, fraud and breach of fiduciary duty. In May 2006, the jury in the case returned a verdict in the Company's favor and awarded the Company \$125 million in damages. The jury found that L-3 Communications Corporation had breached its fiduciary duty to the Company and had committed fraud. The jury awarded the Company \$33 million in compensatory damages and \$92 million in punitive damages. In addition, the jury also found that the Company had breached a confidentiality agreement and awarded L-3 Communications Corporation nominal damages of one dollar. On June 27, 2008, the United States Court of Appeals for the Second Circuit issued a summary order reversing in part, and vacating in part, the judgment of the district court, and remanding the case to the district court for further proceedings. The Second Circuit held that L-3 did not owe the Company a fiduciary duty as a matter of law and reversed the judgment of the district court on our claims for breach of fiduciary duty and constructive fraud. The Second Circuit vacated the judgment of the district court on the Company's claim for actual fraud, and remanded that claim to the district court for further proceedings.

The Company is also involved in various other claims and legal proceedings arising out of the ordinary course of business. In the Company's opinion after consultation with legal counsel, the ultimate disposition of such proceedings will not have a material adverse effect on its financial position, future results of operations, or cash flows. In accordance with SFAS No. 5, Accounting for Contingencies, the Company has not accrued for loss contingencies relating to such matters because the Company believes that, although unfavorable outcomes in the proceedings may be possible, they are not considered by management to be probable or reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company's results of operations, financial position and/or liquidity could be material.

*Contingent Acquisition Obligations*

Under the terms and conditions of the purchase agreements associated with the following acquisitions, the Company may be obligated to make additional payments.



**Table of Contents**

In August 2002, the Company purchased a minority equity interest in CXR Limited. In June 2004, the Company increased its equity interest to approximately 75% and in December 2004, the Company acquired the remaining 25%. As compensation to the selling shareholders for this remaining interest, the Company agreed to make certain royalty payments during the 18 years following the acquisition of its remaining interest. Royalty payments are based on the license of, or sales of products containing technology owned by CXR Limited. As of September 30, 2008, no royalty payments have been earned.

In January 2004, the Company acquired Advanced Research & Applications Corp.. During the seven years following the acquisition, contingent consideration is payable based on its net revenues, provided certain requirements are met. The contingent consideration is capped at \$30.0 million. As of September 30, 2008, no contingent consideration has been earned.

In July 2005, the Company acquired certain assets of InnerStep, B.S.E., Inc. During the seven years following the acquisition, contingent consideration is payable based on its profits before interest and taxes, provided certain requirements are met. The contingent consideration is capped at \$6.0 million. As of September 30, 2008, no contingent consideration has been earned.

In July 2006, the Company completed an acquisition that was not material to its overall Condensed Consolidated Financial Statements. During the two years following the acquisition, contingent compensation is payable based upon profitability. Total contingent consideration is capped at \$0.6 million. During the second quarter of fiscal 2008, \$0.3 million of contingent consideration was paid. As of September 30, 2008, a final payment of \$0.2 million of contingent consideration has been earned and will be paid in fiscal 2009.

*Environmental Contingencies*

The Company is subject to various environmental laws. The Company's practice is to ensure that Phase I environmental site assessments are conducted for each of its properties in the United States at which the Company manufactures products in order to identify, as of the date of such report, potential areas of environmental concern related to past and present activities or from nearby operations. In certain cases, the Company has conducted further environmental assessments consisting of soil and groundwater testing and other investigations deemed appropriate by independent environmental consultants.

During one investigation, the Company discovered soil and groundwater contamination at its Hawthorne, California facility. The Company filed the requisite reports concerning this problem with the appropriate environmental authorities in fiscal 2001. The Company has not yet received any response to such reports, and no agency action or litigation is presently pending or threatened. The Company's site was previously used by other companies for semiconductor manufacturing similar to that presently conducted on the site by us, and it is not presently known who is responsible for the contamination or, if required, the remediation. The groundwater contamination is a known regional problem, not limited to the Company's premises or its immediate surroundings.

The Company has also been informed of soil and groundwater evaluation efforts at a facility that its Ferson Technologies subsidiary previously leased in Ocean Springs, Mississippi. Ferson Technologies occupied the facility until October 2003. The Company believes that the owner and previous occupants of the facility have primary responsibility for any remediation that may be required and have an agreement with the facility's owner under which the owner is responsible for remediation of pre-existing conditions. However, as site evaluation efforts are still in progress, and may be for some time, the Company is unable at this time to ascertain whether Ferson Technologies bears any exposure for remediation costs under applicable environmental regulations.

The Company has not accrued for loss contingencies relating to the above environmental matters because it believes that, although unfavorable outcomes may be possible, they are not considered by the Company's management to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company's results of operations, financial position and/or liquidity could be material.

*Product Warranties*

The Company offers its customers warranties on many of the products that it sells. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified time period after original shipment. Concurrent with the sale of products, the Company records a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. The Company periodically adjusts this provision based on historical and

anticipated experience. The Company charges actual expenses of repairs under warranty, including parts and labor, to this provision when incurred.

**Table of Contents**

The following table presents changes in warranty provisions (in thousands):

	<b>Three months ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
Balance at beginning of period	\$ 7,443	\$ 11,597
Additions	1,332	1,016
Reductions for warranty repair costs	(777)	(1,908)
Balance at end of period	\$ 7,998	\$ 10,705

**8. Income Taxes**

The provision for income taxes is determined using an effective tax rate that is subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as the mix of pre-tax earnings in the various tax jurisdictions in which the Company operates, valuation allowances against deferred tax assets, the recognition or derecognition of tax benefits related to uncertain tax positions, utilization of R&D tax credits and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities along with net operating loss and tax credit carryovers. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made.

**9. Segment Information**

The Company operates in three identifiable industry segments: (i) Security, providing security and inspection systems; (ii) Healthcare, providing patient monitoring, diagnostic cardiology and anesthesia systems; and (iii) Optoelectronics and Manufacturing, providing specialized electronic components for affiliated end-products divisions, as well as for applications in the defense and aerospace markets, among others. The Company also has a Corporate segment that includes executive compensation and certain other general and administrative expenses. Interest expense, and certain expenses related to legal, audit and other professional service fees, are not allocated to industry segments. Both the Security and Healthcare divisions comprise primarily end-product businesses whereas the Optoelectronics and Manufacturing division comprises businesses that primarily supply components and subsystems to original equipment manufacturers, including to the businesses of the Security and Healthcare divisions. All intersegment sales are eliminated in consolidation.

The following table presents segment information (in thousands):

	<b>Three months ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
<b>Revenues by Segment:</b>		
Security division	\$ 48,805	\$ 58,685
Healthcare division	56,598	54,827
Optoelectronics and Manufacturing division, including intersegment revenues	36,372	44,882
Intersegment revenues elimination	(10,762)	(10,233)
<b>Total</b>	<b>\$ 131,013</b>	<b>\$ 148,161</b>

**Revenues by Geography:**

Edgar Filing: OSI SYSTEMS INC - Form 10-Q

North America	\$ 85,740	\$ 106,190
Europe	38,599	35,090
Asia	17,436	17,114
Intersegment revenues elimination	(10,762)	(10,233)
<b>Total</b>	<b>\$ 131,013</b>	<b>\$ 148,161</b>

**Table of Contents**

	<b>Three months ended September 30,</b>	
	<b>2007</b>	<b>2008</b>
<b>Operating income (loss) by Segment:</b>		
Security division	\$ (696)	\$ 3,048
Healthcare division	1,051	(1,824)
Optoelectronics and Manufacturing division	1,339	3,863
Corporate	(3,479)	(4,215)
Eliminations (1)	(130)	178
<b>Total</b>	<b>\$ (1,915)</b>	<b>\$ 1,050</b>

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
<b>Assets by Segment:</b>		
Security division	\$ 199,884	\$ 220,775
Healthcare division	172,038	162,738
Optoelectronics and Manufacturing division	95,615	86,998
Corporate	43,313	28,773
Eliminations (1)	(3,209)	(1,037)
<b>Total</b>	<b>\$ 507,641</b>	<b>\$ 498,248</b>

(1) Eliminations primarily reflect the elimination of intercompany profit in inventory not-yet-realized. This profit will be realized when inventory is shipped to the external customers of the Security and Healthcare divisions.

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**  
**Cautionary Statement**

*Certain statements contained in this quarterly report on Form 10-Q that are not related to historical results, including, without limitation, statements regarding our business strategy, objectives and future financial position, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and involve risks and uncertainties. These forward-looking statements may be identified by the use of forward-looking terms such as anticipate, believe, expect, may, could, likely to, should, or will, or by discussions of strategy that involve predictions which are based upon a number of future conditions that ultimately may prove to be inaccurate. Statements in this quarterly report on Form 10-Q that are forward-looking are based on current expectations and actual results may differ materially. Forward-looking statements involve numerous risks and uncertainties described in this quarterly report on Form 10-Q, our Annual Report on Form 10-K and other documents previously filed or hereafter filed by us from time to time with the Securities and Exchange Commission. Such factors, of course, do not include all factors that might affect our business and financial condition. Although we believe that the assumptions upon which our forward-looking statements are based are reasonable, such assumptions could prove to be inaccurate and actual results could differ materially from those expressed in or implied by the forward-looking statements. All forward-looking statements contained in this quarterly report on Form 10-Q are qualified in their entirety by this statement. We undertake no obligation other than as may be required under securities laws to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

**Critical Accounting Policies and Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions and select accounting policies that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our critical accounting policies are detailed in our Annual Report on Form 10-K for the year ended June 30, 2008.

**Recent Accounting Pronouncements**

We describe recent accounting pronouncements in Item 1 Condensed Consolidated Financial Statements Notes to Condensed Consolidated Financial Statements.

**Executive Summary**

We are a vertically integrated designer and manufacturer of specialized electronic systems and components for critical applications. We sell our products in diversified markets, including homeland security, healthcare, defense and aerospace. We have three operating divisions: (i) Security, providing security and inspection systems; (ii) Healthcare, providing patient monitoring, diagnostic cardiology and anesthesia systems; and (iii) Optoelectronics and Manufacturing, providing specialized electronic components for affiliated end-products divisions, as well as for applications in the defense and aerospace markets, among others.

*Security Division.* Through our Security division, we design, manufacture and market security and inspection systems worldwide for sale primarily to U.S. federal, state and local government agencies as well as to foreign governments. These products are used to inspect baggage, cargo, vehicles and other objects for weapons, explosives, drugs and other contraband as well as to screen people. Revenues from our Security division accounted for 40% and 37% of our total consolidated revenues for the three months ended September 30, 2008 and 2007, respectively.

Following the September 11, 2001 terrorist attacks, U.S. Government spending for the development and acquisition of security and inspection systems increased in response to the attacks and has continued at high levels during its global war on terrorism. This spending has had a favorable impact on our business. However, future levels of such spending could decrease as a result of changing budgetary priorities or could shift to products that we do not provide. Additionally, competition for contracts with the U.S. Government has become more intense in recent years as new competitors and technologies have entered this market.

**Table of Contents**

**Healthcare Division.** Through our Healthcare division, we design, manufacture and market patient monitoring, diagnostic cardiology and anesthesia systems for sale primarily to hospitals and medical centers. Our products monitor patients in critical, emergency and perioperative care areas of the hospital and provide such information, through wired and wireless networks, to physicians and nurses who may be at the patient's bedside, in another area of the hospital or even outside the hospital. Revenues from our Healthcare division accounted for 37% and 43% of our total consolidated revenues for the three months ended September 30, 2008 and 2007, respectively.

The healthcare markets in which we operate are highly competitive. We believe that our customers choose among competing products on the basis of product performance, functionality, value and service. We also believe that price has become an important factor in hospital purchasing decisions because of pressures they are facing to cut costs.

**Optoelectronics and Manufacturing Division.** Through our Optoelectronics and Manufacturing division, we design, manufacture and market optoelectronic devices and value-added manufacturing services worldwide for use in a broad range of applications, including aerospace and defense electronics, security and inspection systems, medical imaging and diagnostics, computed tomography (CT), fiber optics, telecommunications, gaming, office automation, computer peripherals and industrial automation. We also provide our optoelectronic devices and value-added manufacturing services to our own Security and Healthcare divisions. Revenues from our Optoelectronics and Manufacturing division accounted for 23% and 20% of our total consolidated revenues for the three months ended September 30, 2008 and 2007, respectively.

For the three months ended September 30, 2008, we reported an operating profit of \$1.1 million, as compared to an operating loss of \$1.9 million for the comparable prior year period, which represents a \$3 million improvement over our prior year performance. This improvement was driven by a \$17.2 million, or 13%, growth in revenue that generated a \$5.6 million, or 13%, growth in gross profit. Our operating expenses increased by \$1.9 million, or 4%, in support of the 13% growth in revenues as well as in support of next generation products in our Security and Healthcare divisions. In addition, we incurred non-recurring restructuring charges of \$0.8 million in the current year as compared to \$0.1 million in the prior year. Overall, our increased profitability is a result of our continuing efforts to leverage our sales and administrative infrastructure as we grow our businesses.

***Results of Operations for the Three Months Ended September 30, 2008 Compared to Three Months Ended September 30, 2007***

**Net Revenues**

The table below and the discussion that follows are based upon the way in which we analyze our business. See Note 9 to the condensed consolidated financial statements for additional information about our business segments.

<b>(in millions)</b>	<b>Q1 2008</b>	<b>% of Net Sales</b>	<b>Q1 2009</b>	<b>% of Net Sales</b>	<b>\$ Change</b>	<b>% Change</b>
Security division	\$ 48.8	37%	\$ 58.7	40%	\$ 9.9	20%
Healthcare division	56.6	43%	54.8	37%	(1.8)	(3)%
Optoelectronics and Manufacturing division	36.4	28%	44.9	30%	8.5	23%
Intersegment revenues	(10.8)	(8)%	(10.2)	(7)%	0.6	(6)%
<b>Total revenues</b>	<b>\$ 131.0</b>		<b>\$ 148.2</b>		<b>\$ 17.2</b>	<b>13%</b>

Net revenues for the three months ended September 30, 2008, increased \$17.2 million, or 13%, to \$148.2 million from \$131.0 million for the comparable prior year period.

Revenues for the Security division for the three months ended September 30, 2008, increased \$9.9 million, or 20%, to \$58.7 million, from \$48.8 million for the comparable prior year period. The increase was attributable to a \$0.9 million, or 5%, increase in sales of cargo and vehicle inspection systems and a \$9.0 million, or 31%, increase in all other Security division products primarily due to growth in sales of baggage and parcel inspections systems in both the U.S. and in Europe and due to higher service maintenance revenue.

Revenues for the Healthcare division for the three months ended September 30, 2008, decreased \$1.8 million, or 3%, to \$54.8 million, from \$56.6 million for the comparable prior year period. The decrease was primarily attributable to decreased patient monitoring

**Table of Contents**

equipment sales of \$2.4 million, primarily in North America, which we believe is due in part to recent downturn in U.S. economic conditions causing delays in capital spending, and to a decrease in clinical trials services revenue of \$1.2 million. These decreases were partially offset by an increase in diagnostic cardiology equipment sales of \$1.1 million and an increase in supplies and accessories sales of \$0.9 million.

Revenues for the Optoelectronics and Manufacturing division for the three months ended September 30, 2008, increased \$8.5 million, or 23%, to \$44.9 million, from \$36.4 million for the comparable prior year period. The change in revenues was attributable to an increase in contract manufacturing sales of \$8.8 million, including new orders under an existing defense-industry related contract as well as new customer contracts. The change was also due to an increase in commercial optoelectronic sales of \$2.2 million as a result of strong order bookings in the three months ended September 30, 2008. This increase was partially offset by a planned decrease in weapon simulation sales of \$2.3 million, a product line we elected to wind down in fiscal 2008.

**Gross Profit**

(in millions)	Q1 2008	% of Net Sales	Q1 2009	% of Net Sales
Gross profit	\$ 44.1	33.7%	\$ 49.7	33.5%

Gross profit increased \$5.6 million, or 13%, to \$49.7 million for the three months ended September 30, 2008, from \$44.1 million for the comparable prior year period, primarily as a result of the increased revenues discussed above.

The gross profit margin decreased slightly to 33.5%, from 33.7% over the comparable prior year period. Although we experienced marked gross profit improvement in our Security and Optoelectronics and Manufacturing divisions, these improvements were offset by a decrease in sales of products by our Healthcare division, which generally carry a higher gross margin than the products of our other divisions. The favorable change in gross margin in our Security division was attributable to gross margin improvement in cargo and vehicle inspection products resulting from additional efficiencies achieved through improved supply chain management. The favorable change in gross margin in our Optoelectronics and Manufacturing division was attributable to: (i) sales growth in our contract manufacturing business, which allows us to better leverage our fixed manufacturing costs and (ii) a planned decrease in our weapon simulation sales, which historically carried much lower gross margins than the products and services of our other businesses.

**Operating Expenses**

(in millions)	Q1 2008	% of Net Sales	Q1 2009	% of Net Sales	\$ Change	% Change
Selling, general and administrative	\$ 36.2	27.6%	\$ 37.6	25.4%	\$ 1.4	4%
Research and development	9.7	7.4%	10.2	6.9%	0.5	5%
Impairment, restructuring, and other charges	0.1	0.1%	0.8	0.5%	0.7	NM%
Total operating expenses	\$ 46.0	35.1%	\$ 48.6	32.8%	\$ 2.6	6%

**Selling, general and administrative expenses.** Selling, general and administrative (SG&A) expenses consist primarily of compensation paid to sales, marketing and administrative personnel, professional service fees and marketing expenses. For the three months ended September 30, 2008, SG&A expenses increased by \$1.4 million, or 4%, to \$37.6 million, from \$36.2 million for the comparable prior year period. As a percentage of revenues, SG&A expenses for the three months ended September 30, 2008 decreased to 25.4%, from 27.6% for the comparable prior year period. The increase in SG&A expenses during the three months ended September 30, 2008, was primarily attributable to: (i) an increase of \$1.2 million in general and administrative costs to support sales growth in the

Security division, (ii) an increase of approximately \$0.5 million in the Corporate segment, mainly due to increased administrative support and stock-based compensation expense, partially offset by reduced legal and audit expenses, and (iii) an increase of \$0.2 million in general and administrative costs to support sales growth in the Optoelectronics division. As a percentage of sales, SG&A has continued to decrease as we continued to leverage our sales and administrative infrastructure and realized the benefits of restructuring activities undertaken during fiscal 2008.

**Research and development.** Research and development expenses include research related to new product development and product enhancement expenditures. For the three months ended September 30, 2008, such expenses increased \$0.5 million, or 5%, to \$10.2

**Table of Contents**

million, from \$9.7 million for the comparable prior year period. As a percentage of revenues, research and development expenses were 6.9% for the three months ended September 30, 2008, compared to 7.4% for the comparable prior year period. The increase in research and development expenses for the three month period ended September 30, 2008 was primarily attributable to: (i) an increase in spending in the Healthcare division of \$0.3 million in support of next generation products and (ii) an increase in spending within our Security division of \$0.2 million to support new hold (checked) baggage screening products.

**Impairment, restructuring, and other charges.** In fiscal 2007, we initiated a series of restructuring activities that were intended to align our global capacity and infrastructure with demand by our customers and thereby improve our operating efficiencies. During the three months ended September 30, 2008, we continued this initiative to further increase our efficiencies. As a result, we recorded restructuring charges of \$0.8 million. These charges included \$0.5 million in our Healthcare division and \$0.3 million in our Corporate segment, related to facility closure costs and employee severance. During the three months ended September 30, 2007, we recorded restructuring charges of \$0.1 million in our Security division related to employee severance.

**Other Income and Expenses**

	Q1	% of Net	Q1	% of Net	\$	%
(in millions)	2008	Sales	2009	Sales	Change	Change
Interest expense	\$ 1.2	0.9%	\$ 1.0	0.7%	\$ (0.2)	(18)%
Interest income	(0.1)	(0.1)%	(0.1)	(0.1)%		
Total other income and expense	\$ 1.1	0.8%	\$ 0.9	0.6%	\$ (0.2)	(18)%

**Interest expense.** For the three months ended September 30, 2008, we incurred interest expense of \$1.0 million, compared to \$1.2 million for the comparable prior year period. The decrease in interest expense was due to a lower cost of borrowing which was partially offset by higher levels of debt as a result of the repurchase of all outstanding shares of Spacelabs Healthcare previously owned by minority shareholders.

**Income taxes.** For the three months ended September 30, 2008, our income tax provision was \$0.1 million, compared to a benefit of \$1.1 million for the comparable prior year period. Our effective tax rate for the three months ended September 30, 2008 was 34.5%, compared to 35.1% in the comparable prior year period. Our provision for income taxes is dependent on the mix of income from U.S. and foreign locations due to tax rate differences among countries as well as due to the impact of permanent taxable differences.

**Liquidity and Capital Resources**

To date, we have financed our operations primarily through cash flow from operations, proceeds from equity issuances and our credit facilities. Cash and cash equivalents totaled \$21.0 million at September 30, 2008, an increase of \$2.8 million from \$18.2 million at June 30, 2008. The changes in our working capital and cash and cash equivalent balances during the three months ended September 30, 2008 are described below.

	June 30, 2008	September 30, 2008	% Change
Working capital	\$ 195.0	\$ 192.2	(1)%
Cash and cash equivalents	18.2	21.0	15%

**Working Capital.** The decrease in working capital is primarily due to decreases in accounts receivables of \$19.7 million, due to collection on strong sales in the fourth quarter of fiscal 2008 and increases in advances from customers of \$14.1 million due to several large sales in our Security division. These decreases were partially offset by (i) a corresponding decrease in our bank lines of credit of \$9.7 million; (ii) increases in prepayments to vendors, primarily associated with the advances from customers described above; (iii) a \$4.0 million decrease in accounts

payable; (iv) a \$3.9 million increases in inventory, mainly in support of Security division revenue growth; (v) a \$3.2 million reduction in accrued liabilities; and (vi) a \$2.8 million increase in cash.

**Table of Contents**

	<b>Q1 2008</b>	<b>Q1 2009</b>	<b>% Change</b>
Cash provided (used) by operating activities	\$(3.6)	\$ 14.7	505%
Cash used in investing activities	(3.8)	(2.9)	24%
Cash provided (used) by financing activities	6.2	(9.9)	(260)%

*Cash Used in Operating Activities.* Cash flows from operating activities can fluctuate significantly from period to period, as net income (loss), tax timing differences, and other items can significantly impact cash flows. Net cash provided by operations for the three months ended September 30, 2008 was \$14.7 million, an \$18.3 million improvement as compared to the \$3.6 million used in the comparable prior year period. This improvement was partly due to an increase in our net income of \$6.3 million during the three months ended September 30, 2008, after giving consideration to various adjustments to net income for non-operating cash items, including depreciation and amortization, stock-based compensation, deferred taxes and provision for losses on accounts receivable, among others, for both periods. The improvement was also due to better working capital management in the current-year period versus the prior year period, resulting in: (i) a \$13.2 million improvement in advances from customers, (ii) a \$9.8 million improvement in accounts receivable and (iii) a net \$4.8 million improvement in inventory. These efforts were partially offset by changes in accounts payables of \$10.6 million and other operating asset and liability accounts of \$5.0 million.

*Cash Used in Investing Activities.* Net cash used in investing activities was \$2.9 million for the three months ended September 30, 2008, compared to \$3.8 million for the three months ended September 30, 2007. During the three months ended September 30, 2008, we invested \$2.2 million in capital expenditures, compared to \$2.6 million in capital expenditures during the comparable prior year period. In addition, during the comparable prior year period, we repurchased shares of Spacelabs Healthcare stock for \$0.4 million.

*Cash Provided by Financing Activities.* Net cash used in financing activities was \$9.9 million for the three months ended September 30, 2008, compared to net cash provided by financing activities of \$6.2 million for the three months ended September 30, 2007. During the three months ended September 30, 2008, we paid down our revolving lines of credit by \$9.4 million and we also paid down our ongoing scheduled debt and capital leases by an additional \$2.1 million. In the prior year period, we received net proceeds from our credit facilities and other debt obligations of \$5.3 million to fund working capital requirement and to repurchase Spacelabs Healthcare stock. In addition, we received cash of \$1.6 million from proceeds from equity instruments for the three months ended September 30, 2008 as compared to \$0.9 million for the comparable prior year period.

**Borrowings**

Outstanding lines of credit and current and long-term debt totaled \$62.6 million at September 30, 2008, a decrease of \$11.7 million from \$74.3 million at June 30, 2008.

We maintain a credit agreement with certain lenders allowing for borrowings up to \$124.5 million. The credit agreement consists of a \$74.5 million, five-year, revolving credit facility (including a \$45 million sub-limit for letters-of-credit) and a \$50 million five-year term loan. Borrowings under this agreement bear interest at either (i) the London Interbank Offered Rate (LIBOR) plus between 2.00% and 2.50% or (ii) the bank's prime rate plus between 1.00% and 1.50%. The rates are determined based on our consolidated leverage ratio. As of September 30, 2008, the effective, weighted-average interest rate under the credit agreement was 5.5%. Our borrowings under the credit agreement are guaranteed by substantially all of our direct and indirect wholly-owned subsidiaries and are secured by substantially all of our assets and the assets of our subsidiary guarantors. The agreement contains various representations, warranties, affirmative, negative and financial covenants, and conditions of default customary for financing agreements of this type. As of September 30, 2008, \$46.5 million was outstanding under the term loan, no amount was outstanding under the revolving credit facility, and \$13.8 million was outstanding under the letter-of-credit facility.

Several of our foreign subsidiaries maintain bank lines-of-credit, denominated in local currencies, to meet short-term working capital requirements and for the issuance of letters-of-credit. As of September 30, 2008, \$22.9 million was outstanding under the letter-of-credit facilities, while no debt was outstanding. As of September 30, 2008, the total

amount available under these credit facilities was \$32.6 million, with a total cash borrowing sub-limit of \$8.1 million. As of September 30, 2008, the weighted average interest rate of these facilities was 7.1% per annum.

**Table of Contents**

In December 2004, we entered into a bank loan of \$5.3 million to fund the acquisition of land and buildings in the U.K. The loan is payable over a 20-year period, with quarterly installments of £34,500 (approximately \$63,000 as of September 30, 2008). The loan bears interest at British pound-based LIBOR plus 1.2%, payable on a quarterly basis. As of September 30, 2008, \$4.1 million remained outstanding under this loan at an interest rate of 7.5% per annum. Our long-term debt consisted of the following:

	<b>June 30, 2008</b>	<b>September 30, 2008</b>
Five-year term loan due in fiscal 2013	\$ 47,763	\$ 46,513
Twenty-year term loan due in fiscal 2025	4,539	4,126
Capital leases	2,193	1,938
Other	1,189	1,058
	55,684	53,635
Less current portion of long-term debt	6,593	7,094
Long-term portion of debt	\$ 49,091	\$ 46,541

We anticipate that existing cash borrowing arrangements and future access to capital markets should be sufficient to meet our cash requirements for the foreseeable future. However, our future capital requirements will depend on many factors, including future business acquisitions, litigation, stock repurchases and levels of research and development spending, among other factors and the adequacy of available funds will depend on many factors, including the success of our businesses in generating cash, continued compliance with financial covenants contained in our credit facility, and the capital markets in general, among other factors.

**Stock Repurchase Program**

Our Board of Directors has authorized a stock repurchase program under which we can repurchase up to 3,000,000 shares of our common stock. During the three months ended September 30, 2008, we did not repurchase any shares under this program and 1,330,973 shares were available for additional repurchase under the program as of September 30, 2008. We retire the treasury shares as they are repurchased and record them as a reduction in the number of shares of common stock issued and outstanding in our condensed consolidated financial statements.

**Dividend Policy**

We have never paid cash dividends on our common stock and have no plans to do so in the foreseeable future.

**Contractual Obligations**

Under the terms and conditions of the purchase agreements associated with the following acquisitions, we may be obligated to make additional payments:

In August 2002, we purchased a minority equity interest in CXR Limited. In June 2004, we increased our equity interest to approximately 75% and in December 2004, we acquired the remaining 25%. As compensation to the selling shareholders for this remaining interest, we agreed to make certain royalty payments during the 18 years following the acquisition of its remaining interest. Royalty payments are based on the license of, or sales of products containing technology owned by CXR Limited. As of September 30, 2008, no royalty payments have been earned.

In January 2004, we acquired Advanced Research & Applications Corp. During the seven years following the acquisition, contingent consideration is payable based on its net revenues, provided certain requirements are met. The contingent consideration is capped at \$30.0 million. As of September 30, 2008, no contingent consideration has been earned.

In July 2005, we acquired certain assets of InnerStep, B.S.E., Inc. During the seven years following the acquisition, contingent consideration is payable based on its profits before interest and taxes, provided certain requirements are met. The contingent consideration is capped at \$6.0 million. As of September 30, 2008, no contingent consideration has been earned.



**Table of Contents**

In July 2006, we completed another acquisition that was not material to our overall Condensed Consolidated Financial Statements. During the two years following the acquisition, contingent compensation is payable based upon profitability. Total contingent consideration is capped at \$0.6 million. During the second of fiscal 2008, \$0.3 million of contingent consideration was paid. As of September 30, 2008, a final payment of \$0.2 million of contingent consideration has been earned and is expected to be paid in fiscal 2009.

**Off Balance Sheet Arrangements**

As of September 30, 2008, we did not have any significant off balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

For the three months ended September 30, 2008, no material changes occurred with respect to market risk as disclosed in our Annual Report on Form 10-K for the fiscal year ended June 30, 2008.

**Market Risk**

We are exposed to certain market risks, which are inherent in our financial instruments and arise from transactions entered into in the normal course of business. We may enter into derivative financial instrument transactions in order to manage or reduce market risk in connection with specific foreign-currency-denominated transactions. We do not enter into derivative financial instrument transactions for speculative purposes.

We are subject to interest rate risk on our short-term borrowings under our bank lines of credit. Borrowings under these lines of credit do not give rise to significant interest rate risk because these borrowings have short maturities and are borrowed at variable interest rates. Historically, we have not experienced material gains or losses due to interest rate changes.

**Foreign Currency**

We maintain the accounts of our operations in each of the following countries in the following currencies: Finland, France, Germany, Italy and Greece (Euros), Singapore (Singapore dollars and U.S. dollars), Malaysia (Malaysian ringgits), United Kingdom (U.K. pounds), Norway (Norwegian kroners), India (Indian rupees), Indonesia (Indonesian rupiah), Hong Kong (Hong Kong dollars), China (Chinese renminbi), Canada (Canadian dollars), Australia (Australian dollars) and Cyprus (Cypriot pounds). Foreign currency financial statements are translated into U.S. dollars at period-end rates, with the exception of revenues, costs and expenses, which are translated at average rates during the reporting period. We include gains and losses resulting from foreign currency transactions in income, while we exclude those resulting from translation of financial statements from income and include them as a component of accumulated other comprehensive income (AOCI). Transaction gains and losses, which were included in our condensed consolidated statement of operations, amounted to a gain of approximately \$0.8 million during the three months ended September 30, 2008, as compared to a gain of \$0.1 million for the comparable prior year period. Furthermore, a 10% appreciation of the U.S. dollar relative to the local currency exchange rates would have resulted in a net increase in our operating income of approximately \$2 million in first quarter of fiscal 2008. Conversely, a 10% depreciation of the U.S. dollar relative to the local currency exchange rates would have resulted in a net decrease in our operating income of approximately \$2 million in first quarter of fiscal 2008.

**Use of Derivatives**

We may, from time to time, purchase foreign exchange contracts, in order to attempt to reduce foreign exchange transaction gains and losses, or enter into interest rate swaps. As of September 30, 2008, we had an \$8.3 million foreign currency forward contract to sell Polish zloty in anticipation of the sale and settlement in the second quarter of fiscal 2009 of products denominated in Polish zloty. Pursuant to SFAS 133, the entire amount of this forward contract is considered a cash flow hedge. As a result, the gain on this forward contract for the three months ended September 30, 2008 of \$0.1 million has been reported as a component of other comprehensive income in the condensed consolidated financial statements. Such amount will be reclassified into earnings in the same period that the related transaction is completed, which we anticipate to occur in the second quarter of fiscal 2009.

**Table of Contents**

**Importance of International Markets**

International markets provide us with significant growth opportunities. However, the following events, among others, could adversely affect our financial results in subsequent periods: periodic economic downturns in different regions of the world, changes in trade policies or tariffs, wars and other forms of political instability. We continue to perform ongoing credit evaluations of our customers' financial condition and, if deemed necessary, we require advance payments for sales. We monitor economic and currency conditions around the world to evaluate whether there may be any significant effect on our international sales in the future. Due to our overseas investments and the necessity of dealing in local currencies in many foreign business transactions, we are at risk with respect to foreign currency fluctuations.

**Inflation**

We do not believe that inflation had a material impact on our results of operations during the three months ended September 30, 2008.

**Interest Rate Risk**

We classify all highly liquid investments with maturity of three months or less as cash equivalents and record them in the balance sheet at fair value. Short-term investments comprise high-quality marketable securities.

**Item 4. Controls and Procedures**

*(a) Evaluation of Disclosure Controls and Procedures*

As of September 30, 2008, the end of the period covered by this report, our management, including our Chief Executive Officer and our Chief Financial Officer, reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended). Such disclosure controls and procedures are designed to ensure that material information we must disclose in this report is recorded, processed, summarized and filed or submitted on a timely basis. Based upon that evaluation our management, Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of September 30, 2008.

*(b) Changes in Internal Control over Financial Reporting*

There has been no change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) during the quarter ended September 30, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**PART II OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are involved in various claims and legal proceedings which have been previously disclosed in our quarterly and annual reports. The results of such legal proceedings cannot be predicted with certainty. Should we fail to prevail in any of these legal matters or should several of these legal matters be resolved against us in the same reporting period, the operating results of a particular reporting period could be materially adversely affected.

We are also involved in various other claims and legal proceedings arising out of the ordinary course of business which have not been previously disclosed in our quarterly and annual reports. In our opinion, after consultation with legal counsel, the ultimate disposition of such proceedings will not likely have a material adverse effect on our financial position, future results of operations or cash flows.

**Item 1A. Risk Factors**

The discussion of our business and operations in this Quarterly Report on form 10-Q should be read together with the risk factors contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2008, filed with the Securities and Exchange Commission, which describe various risks and uncertainties to which we are or may become subject. Additionally, as a result of the current instability of the world's financial markets, some of our suppliers and customers who rely on the credit or equity markets for access to capital may be negatively impacted. This risk and the risks and uncertainties described in our Annual Report have the potential to affect our business, financial condition, results of operations, cash flows, strategies or prospects in a material and adverse manner.

**Item 6. Exhibits**

31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

**Table of Contents**

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Hawthorne, State of California on the 30th day of October 2008.

**OSI SYSTEMS, INC.**

By: /s/ Deepak Chopra  
Deepak Chopra  
President and Chief Executive Officer

By: /s/ Alan Edrick  
Alan Edrick  
Executive Vice President and  
Chief Financial Officer